Gamunex Connexions provides financial assistance for eligible patients, benefits investigation services, and patient education resources.
To access support for your patients and the healthcare team,
call Gamunex Connexions
1-888-MYGAMUNEX (1-888-694-2686)
Monday through Friday 8 AM to 8 PM ET
Patients can get similar support if they're receiving XEMBIFY for PIDD
XEMBIFY® is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.1
Gamunex Connexions offers financial support programs to help with medication costs for eligible patients
Copay Assistance Program
- For eligible patients* with commercial or private insurance, copay assistance up to $10,000 per calendar year is available to help with copayments, coinsurance, and deductibles.
- To request copay assistance, the infusion provider or specialty pharmacy enters the patient’s information into the Gamunex Connexions copay assistance portal.
- The team at Gamunex Connexions is available to answer questions about accessing the Copay Assistance Program.
How to request copay assistance for your patient
Medical Billing
- REGISTER your facility (one-time registration) at the medical billing portal.
- SUBMIT A REQUEST in the portal with your patient's estimated financial responsibility within 90 days of the dispense date.
- UPLOAD THE EXPLANATION OF BENEFITS in the portal within 180 days of the date the request was submitted.
Pharmacy Billing
SUBMIT a claim to the primary payer first. If your patient requires copay assistance, submit a secondary claim through your NCPDP system using the following:
BIN: 016664
PCN: MEDMONK
CARDHOLDER: MEDMONK
For more information or assistance, contact Medmonk Support: 1-866-234-3732.
Patient Assistance Program (PAP)
- For eligible patients without insurance, the PAP provides medication free of charge.
- Requirements for qualification include:
- Total household income less than or equal to 400% of the federal poverty level
- Patient is uninsured or has an insurance plan that does not cover specialty pharmaceuticals
- Prescribed GAMUNEX-C for PIDD or CIDP
- Resident of the United States, excluding territories
- Patient may not be enrolled in a government-funded healthcare program, such as Medicare, Medigap, Medicaid, VA, DOD, or Tricare
How to request the PAP for your patient:
- Complete and submit PAP Application Form and Prescription Referral Form.
- Patient enrollment in Gamunex Connexions is also needed for PAP services.
The team at Gamunex Connexions will evaluate your patient’s eligibility for the PAP and contact you and/or your patient if more information is needed.
For help with the PAP application process, call Gamunex Connexions 1-888-MYGAMUNEX (1-888-694-2686).
Tell your patients about Gamunex Connexions and encourage them to enroll
Our team of dedicated case managers is ready to talk with your patients and support them by:
- Helping them understand insurance coverage and financial assistance programs
- Answering questions about their disease and treatment
- Providing information about organizations that offer additional resources and connection with other patients
You can start the enrollment process on behalf of your patients, and Gamunex Connexions will contact the patients to complete the process. Patients can also enroll on their own.
Forms for Gamunex Connexions
Download these forms to request support for your patients
Important Safety Information
View CloseXEMBIFY® (immune globulin subcutaneous, human–klhw), 20% and GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) are immune globulins indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older.
XEMBIFY is a 20% solution for subcutaneous administration only. GAMUNEX-C is a 10% solution for intravenous and subcutaneous administration in PIDD.
WARNING: THROMBOSIS
Thrombosis may occur with immune globulin products, including XEMBIFY and GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer XEMBIFY and GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
WARNING: RENAL DYSFUNCTION and ACUTE RENAL FAILURE
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with GAMUNEX-C in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs.
Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose. GAMUNEX-C does not contain sucrose.
For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable.
Contraindications
XEMBIFY and GAMUNEX-C are contraindicated in:
Patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.
IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Warnings and Precautions
Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY and GAMUNEX-C. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY and GAMUNEX-C contain IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.
Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY and GAMUNEX-C. Conduct a thorough neurological exam on patients exhibiting signs and symptoms of AMS to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae.
Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY and GAMUNEX-C, even in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia. Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIG treatment, including GAMUNEX-C.
Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY and GAMUNEX-C do not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function (including blood urea nitrogen [BUN], serum creatinine, and urine output) prior to the initial infusion and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation.
Hemolysis. XEMBIFY and GAMUNEX-C may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing.
Transfusion-related acute lung injury (TRALI). Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY and GAMUNEX-C. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.
Transmissible infectious agents. Because XEMBIFY and GAMUNEX-C are made from human blood, they may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Interference with lab tests. Passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation.
Adverse Reactions
The most common adverse reactions in ≥ 5% of subjects in clinical trials were:
XEMBIFY
PIDD, subcutaneous: local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea.
GAMUNEX-C
PIDD, subcutaneous: local infusion-site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, migraine, myalgia, viral infection, and pyrexia.
PIDD, intravenous: cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, and sinusitis.
The most serious adverse reaction in clinical studies with GAMUNEX-C in PIDD was an exacerbation of autoimmune pure red cell aplasia in 1 subject.
Drug Interactions
Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella).
Please see accompanying full Prescribing Information for XEMBIFY.
Please see accompanying full Prescribing Information for GAMUNEX-C.
XEMBIFY® (immune globulin subcutaneous, human–klhw), 20% and GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) are immune globulins indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older.
XEMBIFY is a 20% solution for subcutaneous administration only. GAMUNEX-C is a 10% solution for intravenous and subcutaneous administration in PIDD.
WARNING: THROMBOSIS
Thrombosis may occur with immune globulin products, including XEMBIFY and GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer XEMBIFY and GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
WARNING: RENAL DYSFUNCTION and ACUTE RENAL FAILURE
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with GAMUNEX-C in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs.
Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose. GAMUNEX-C does not contain sucrose.
For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable.
Contraindications
XEMBIFY and GAMUNEX-C are contraindicated in:
Patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.
IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Warnings and Precautions
Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY and GAMUNEX-C. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY and GAMUNEX-C contain IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.
Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY and GAMUNEX-C. Conduct a thorough neurological exam on patients exhibiting signs and symptoms of AMS to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae.
Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY and GAMUNEX-C, even in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia. Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIG treatment, including GAMUNEX-C.
Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY and GAMUNEX-C do not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function (including blood urea nitrogen [BUN], serum creatinine, and urine output) prior to the initial infusion and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation.
Hemolysis. XEMBIFY and GAMUNEX-C may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing.
Transfusion-related acute lung injury (TRALI). Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY and GAMUNEX-C. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.
Transmissible infectious agents. Because XEMBIFY and GAMUNEX-C are made from human blood, they may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Interference with lab tests. Passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation.
Adverse Reactions
The most common adverse reactions in ≥ 5% of subjects in clinical trials were:
XEMBIFY
PIDD, subcutaneous: local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea.
GAMUNEX-C
PIDD, subcutaneous: local infusion-site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, migraine, myalgia, viral infection, and pyrexia.
PIDD, intravenous: cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, and sinusitis.
The most serious adverse reaction in clinical studies with GAMUNEX-C in PIDD was an exacerbation of autoimmune pure red cell aplasia in 1 subject.
Drug Interactions
Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella).
Please see accompanying full Prescribing Information for XEMBIFY.
Please see accompanying full Prescribing Information for GAMUNEX-C.
Important Safety Information
XEMBIFY® (immune globulin subcutaneous, human–klhw), 20% and GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) are immune globulins indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older.
XEMBIFY is a 20% solution for subcutaneous administration only. GAMUNEX-C is a 10% solution for intravenous and subcutaneous administration in PIDD.
WARNING: THROMBOSIS
Thrombosis may occur with immune globulin products, including XEMBIFY and GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer XEMBIFY and GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
WARNING: RENAL DYSFUNCTION and ACUTE RENAL FAILURE
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with GAMUNEX-C in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs.
Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose. GAMUNEX-C does not contain sucrose.
For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable.
Contraindications
XEMBIFY and GAMUNEX-C are contraindicated in:
Patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.
IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Warnings and Precautions
Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY and GAMUNEX-C. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY and GAMUNEX-C contain IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.
Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY and GAMUNEX-C. Conduct a thorough neurological exam on patients exhibiting signs and symptoms of AMS to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae.
Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY and GAMUNEX-C, even in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia. Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIG treatment, including GAMUNEX-C.
Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY and GAMUNEX-C do not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function (including blood urea nitrogen [BUN], serum creatinine, and urine output) prior to the initial infusion and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation.
Hemolysis. XEMBIFY and GAMUNEX-C may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing.
Transfusion-related acute lung injury (TRALI). Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY and GAMUNEX-C. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.
Transmissible infectious agents. Because XEMBIFY and GAMUNEX-C are made from human blood, they may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Interference with lab tests. Passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation.
Adverse Reactions
The most common adverse reactions in ≥ 5% of subjects in clinical trials were:
XEMBIFY
PIDD, subcutaneous: local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea.
GAMUNEX-C
PIDD, subcutaneous: local infusion-site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, migraine, myalgia, viral infection, and pyrexia.
PIDD, intravenous: cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, and sinusitis.
The most serious adverse reaction in clinical studies with GAMUNEX-C in PIDD was an exacerbation of autoimmune pure red cell aplasia in 1 subject.
Drug Interactions
Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella).
Please see accompanying full Prescribing Information for XEMBIFY.
Please see accompanying full Prescribing Information for GAMUNEX-C.
Terms to know
CIDP, chronic inflammatory demyelinating polyneuropathy; IG, immune globulin.
Reference
- XEMBIFY Prescribing Information, Grifols. July 2024.